Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Renovorx Inc (NQ: RNXT )

1.315 -0.055 (-4.01%)
Streaming Delayed Price Updated: 10:29 AM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Renovorx Inc

< Previous 1 2 3 Next >
RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15
From RenovoRx, Inc.
Via Business Wire
RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the LD Micro Invitational XIII Conference
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
From RenovoRx, Inc.
Via Business Wire
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023
From RenovoRx, Inc.
Via Business Wire
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
From RenovoRx, Inc.
Via Business Wire
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
From RenovoRx, Inc.
Via Business Wire
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
From RenovoRx, Inc.
Via Business Wire
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
From RenovoRx, Inc.
Via Business Wire
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
From RenovoRx, Inc.
Via Business Wire
RenovoRx, Inc. Full-year 2022 Results Provide Clues Supporting A Near-Term Catalyst-Fueled Breakout ($RNXT)
Via AB Newswire
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
From RenovoRx, Inc.
Via Business Wire
RenovoRx, Inc. Shares Surge 117% YTD As Multiple Catalysts Come Into Focus ($RNXT)
Via AB Newswire
RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023
From RenovoRx, Inc.
Via Business Wire
RenovoRx, Inc. Shares Rally As RenovoTAMP Cancer Treatment Platform Continues To Attract Sector Attention ($RNXT)
Via AB Newswire
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment
From RenovoRx, Inc.
Via Business Wire
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports Third Quarter 2022 Financial Results
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in Upcoming October 2022 Investor Conferences
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer
From RenovoRx, Inc.
Via Business Wire
RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022
From RenovoRx, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.